Business
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a 94.5% (95% CI: 86.1, 97.9) durability of response (DOR) at six months by Kaplan-Meier estimate, in the ongoing Phase 3 UTOPIA trial of UGN-103 (mitomycin) for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMI
About this update from Urogen Pharma Ltd.
[{"type":"image","alt":"UroGen Pharma Ltd.","displaySize":"","headline":null,"caption":"UroGen Pharma Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/17a882b70e8712b054a21e7ea3661787"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gfSsx4lS3V0xpLK4VA4i6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMw--/https://media.zenfs.com/en/globenewswire.com/17a882b70e8712b054a21e7ea3661787","width":300,"height":88},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/gfSsx4lS3V0xpLK4VA4i6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMw--/https://media.zenfs.com/en/globenewswire.com/17a882b70e8712b054a21e7ea3661787","width":300,"height":88}},"lazy":false},{"type":"text","content":"PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a 94.5% (95% CI: 86.1, 97.9) durability of response (DOR) at six months by Kaplan-Meier estimate, in the ongoing Phase 3 UTOPIA trial of UGN-103 (mitomycin) for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The six-month results from UTOPIA are generally consistent with the 91.9% (95% CI: 86.9, 95.0) six-month DOR observed with ZUSDURI™ (mitomycin) for intravesical therapy in its pivotal ENVISION trial. ZUSDURI is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for adult patients with recurrent LG-IR-NMIBC.","length":847,"tagName":"p"},{"type":"text","content":"Based on the consistency of UTOPIA data with the results of the ENVISION trial studying ZUSDURI in patients meeting the same eligibility criteria and alignment with the FDA, UroGen remains on track to submit a New Drug Application (NDA) for UGN-103 in the third quarter of 2026.","length":278,"tagName":"p"},{"type":"text","content":"“The durability of response observed at six months with UGN-103 in the UTOPIA trial is generally consistent with that observed in the pivotal ENVISION trial of ZUSDURI, and highlights the potential to further advance care for adult patients with recurrent LG-IR-NMIBC,” said Abishek Srivastava, MD, Urologic Oncologist at Atlantic Urology Clinics, Myrtle Beach, SC, START Center for Cancer R...